Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 95 publications
Synthetic long peptide and DNA personalized cancer vaccines induce robust neoantigen-specific T cell responses in pancreatic cancer.
Journal: Science advances
Published: September 04, 2026
Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRASG12C mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised phase 1/2 trials.
Journal: The lancet. Gastroenterology & hepatology
Published: April 03, 2025
Efficacy and safety of glecirasib in solid tumors with KRAS G12C mutation: A pooled analysis of two phase I/II trials.
Journal: Cancer communications (London, England)
Published: March 24, 2025
Glecirasib plus sitneprotafib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1/2a trial.
Journal: The Lancet. Respiratory medicine
Published: February 19, 2025
Population Pharmacokinetics of Fruquintinib, a Selective Oral Inhibitor of VEGFR -1, -2, and -3, in Patients with Refractory Metastatic Colorectal Cancer.
Journal: Journal of clinical pharmacology
Published: October 01, 2024
Neoadjuvant BMS-813160, Nivolumab, Gemcitabine, and Nab-Paclitaxel for Patients with Pancreatic Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 11, 2024
Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial.
Journal: Nature medicine
Published: June 11, 2024
Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers.
Journal: Science (New York, N.Y.)
Published: June 06, 2024
Neoantigen DNA vaccines are safe, feasible, and induce neoantigen-specific immune responses in triple-negative breast cancer patients.
Journal: Genome medicine
Published: November 26, 2023
ERBB2 (HER2) amplifications and co-occurring KRAS alterations in the circulating cell-free DNA of pancreatic ductal adenocarcinoma patients and response to HER2 inhibition.
Journal: Frontiers in oncology
Published: November 15, 2023
Correction: Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: a Phase I Dose Escalation and Expansion Study.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 14, 2023
First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors.
Journal: Journal for immunotherapy of cancer
Published: October 04, 2023
Last Updated: 09/26/2026